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Genotoxicity evaluation of Oryeong-san
water extract using in vitro and in vivo tests
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Abstract
Background: Oryeong-san, a mixture of five herbal plants, is a well-known therapy for renal-associated diseases
such as those manifesting edema, dysuria, and oliguria.
Methods: In the present study, we investigatee the potential genotoxic effects of a water extract of Oryeong-san
(ORSE) in three mutagenicity assays (an in vitro bacterial reverse mutation assay (Ames test) with Salmonella
typhimurium and Escherichia coli strains, an in vitro mammalian chromosomal aberration test using Chinese hamster
lung cells, and an in vivo micronucleus test using ICR mice bone marrow).
Results: ORSE showed no genotoxicity in the Ames test up to 5000 μg/plate; the in vitro chromosome aberration
test showed no significant structural aberrations with and without the S9 mix up to 5000 μg/mL, or the in vivo
micronucleus test up to 2000 mg/kg body weight.
Conclusions: In conclusion, under the current test conditions, ORSE seems safe for use; however, other
genotoxicity tests (e.g. sister-chromatid exchange or Comet) or chronic toxicity tests are warranted.
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Background
The global demand for herbal medicinal products has
increased significantly in recent years. “By 2003 in the
United States alone, over 1500 herbal products sold were
nutraceuticals, which are exempt from extensive preclin-
ical efficacy and toxicity testing by the US Food and
Drug Administration” [1]. Obidike and Salawu reported
that despite the growing market demand for herbal med-
icines, there are still concerns associated with not only
their use, but also their safety. The primary purpose of
toxicological assessment of any herbal medicine is to
identify side effects and to determine limits of exposure
at which such effects occur [2]. Less than 10% of herbal
products in the world market are truely standardized to
known major active components and quality control
measures are not always diligently adhered to [3]. The
traditional herbal medicine Oryeong-san (also known
as Wulingsan in traditional Chinese medicine and as
Gorei-san in Japanese Kampo medicine) is a mixture
of five herbal preparations (Alisma orientale (Sam)
Juzepzuk, Poria cocos, Atractylodes japonica Koidzumi
et Kitagawa, Polyporus umbellatus Fries, and Cinna-
momum cassia J.Presl). Oryeong-san is well known for
the treatment of renal diseases, dysuria, manifesting
edema, and oliguria [4]. Oryeong-san also has antihyper-
tensive [5], antidiabetic [6], antioxidative [7], and antigas-
tric [8] properties, and confers hepatic protection.
Genotoxicity is a special type of toxicity, because it is
often the most difficult to detect. The aim of a geno-
toxic test is to detect mutagenic carcinogens as well as
to detect germ cell mutagens with the goal of limiting
human exposure to these potentially dangerous chemi-
cals [9]. The purpose of the present study was to evalu-
ate the safety of an aqueous extract of Oryeong-san
(ORSE) and its potential genotoxicity. We assessed
these properties using a standard battery of tests rec-
ommended by the Korea Food and Drug Administra-
tion: a bacterial reverse mutation test (Ames test), a
chromosome aberration test, and an in vivo micronu-
cleus (MN) test.
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The reference standards, cinnamaldehyde and coumarin,
were purchased from Wako (Osaka, Japan) and Sigma-
Aldrich (St. Louis, CA, USA). The purity of the two ref-
erence standards was ≥98.0% by HPLC analysis. The
HPLC-grade solvents, acetonitrile and water, methanol,
were obtained from J.T. Baker (Phillipsburg, NJ, USA).
The Oryeong-san samples used in this study consisted of
five herbal medicines (Table 1) and were purchased from
Kwangmyungdang Medicinal herbs (Ulsan, Korea). All
herbal medicines were taxonomically confirmed by Pro-
fessor Je-Hyun Lee, Dongguk University, Korea. Voucher
specimens (2013-KE17-1 through KE17-5) have been
deposited at the Herbal Medicine Formulation Research
Group, Korea Institute of Oriental Medicine.
Preparation of standard and sample solutions
Standard stock solutions of coumarin and cinnamalde-
hyde were dissolved in methanol at 1.0 mg/mL and
stored below 4°C. A decoction of Oryeong-san, which
was composed of 5 herbal medicines (Table 1), was
prepared in SungIl Bioex Co. Ltd. (Hwaseong, Korea).
Briefly, the mixture (120.0 kg. i.e. about 4270.46 times
of composition of single dose) of 5 herbal medicine
was extracted in distilled water (1200 L) at 80°C for 2
h by reflux. The solution was freeze-dried to about
21.8 kg of water extract powder (yield: 18.17%). Ly-
ophilized Oryeong-san extract (200 mg) was dissolved
in distilled water (20 mL). The solution was filtered
through a 0.2 μm membrane filter (Woongki Science,
Seoul, Korea).
HPLC analysis of ORSE
HPLC simultaneous determination was performed using
an LC-20A HPLC system (Shimadzu, Kyoto, Japan), con-
sisting of an LC-20AT pump, DGU-20A3 online degas-
ser, SPD-M20A detector, SIL-20AC autosampler, and
CTO-20A column oven. The data processor employed
LC solution software (version 1.24, Shimadzu). The sep-
aration of three compounds was conducted using a
Gemini C18 (250 mm × 4.6 mm; 5 μm, Phenomenex,
Torrance, CA, USA) and column oven temperature was
maintained at 40°C. The mobile phases comprised water
(A) and acetonitrile (B). The gradient condition was as
follows: 0–30 min, 25–100% B; 30–35 min, 100–25% B;
35–50 min, 25% B. The analysis was conducted at a flow
rate of 1.0 mL/min with PDA detection at 280 nm. The
injection volume was 10 μL.
Bacterial reverse mutation assay (Ames test)
Bacterial reverse mutation assays were conducted as
described previously [10]. Salmonella typhimurium
strains TA98 and TA1537 (to detect frame-shift muta-
gens), TA100, and TA1535, and Escherichia coli strain
WP2uvrA (to detect base pair-substitution mutagens)
were obtained from Molecular Toxicology Inc. (Boone,
NC, USA) and were used as the tester strains. To
evaluate the toxicity and solubility (precipitation) of
ORSE, a pilot experiment was performed with all bac-
terial strains (data not shown). The positive control
factors were 2-nitrofluorene (2-NF), 2-aminoanthracene
(2-AA), 9-aminoacridine (9-AA), 4-nitroquinoline X-oxide
(4NQO), and benzo (a) pyrene (BP). A dose range-finding
test was performed to determine the highest concentra-
tion for the present study, which was performed with the
five tester strains at concentrations of 0, 1250, 2500, and
5,000 μg/plate with and without the S9 mixture. The
number of revertant colonies did not increase to more
than twice the value observed in the controls for any
of the tester stains. However, there were increased
numbers of revertant colonies of TA1535 with the S9
mixture. Based on these results, a dose of 5,000 μg/
plate was selected as the maximum dose. Briefly, vari-
ous concentrations of ORSE were incubated with the
tester strains at 37°C for 48 h in the presence or ab-
sence of metabolic activation by the S9 mixture along
with vehicle and positive controls containing the fol-
lowing combinations of substances and doses: 2-AA at
2 μg/plate vs. TA1535 with or without the S9 mixture
and at 4 μg/plate vs. WP2uvrA with the S9 mixture; 9-
AA at 50 μg/plate vs. TA1537 without the S9 mixture;
BP at 2 μg/plate vs. TA98 with or without the S9 mix-
ture and vs. TA100 and TA1537 with the S9 mixture);
2-NF at 2 μg/plate vs. TA98 without the S9 mixture;
4NQO at 0.5 μg/plate vs. WP2uvrA without the S9
mixture; and sodium azide at 0.5 μg/plate vs. TA100
and TA1535 without the S9 mixture. Each concentra-
tion of ORSE was tested in triplicate. A result was
deemed positive if there was a concentration-related
increase over the range tested and/or a reproducible
increase at one or more concentrations in the number
of revertant colonies per plate in at least one strain






9.375 Alismatis Rhizoma Yeongcheom,
Korea












1.875 Cinnamomi Cortex Vietnam
Total 28.1
Lee et al. BMC Complementary and Alternative Medicine  (2015) 15:273 Page 2 of 8
with or without the S9 mixture. An antibacterial effect
(cytotoxicity) was defined as a clearing or diminution of
the background lawn, the appearance of microcolonies,
and/or a decrease of > 50% in the number of colonies
compared with the relevant vehicle control.
Chromosome aberration test
Chromosome aberration tests were conducted as de-
scribed previously [10] with minor modification as de-
scribed by Ishidate et al. [11] and Dean and Danford [12].
Chinese hamster lung (CHL) cells were obtained from
American Type Culture Collection (Manassas, VA, USA)
in 2004. The cells were thawed in culture medium and
then grown for more than 7 days as a monolayer. Cells
were cultured in reconstituted MEM (Gibco-Invitrogen,
USA) supplemented with 2.2 g of sodium bicarbonate,
292 mg of l-glutamine, streptomycin sulfate (100 μg/
mL), penicillin G · Na (105 units), and 10% (v/v) fetal
bovine serum (FBS; Gibco-Invitrogen, USA) per liter.
The cultures were incubated at 37°C in a humidified at-
mosphere with 1.5% CO2. A preliminary dose range-
finding study was performed to determine the highest
concentration for this study. Using the results from the
dose range-finding study, the dose range for the present
study was designed to quantify the solubility and cyto-
toxicity of GBT. Ethyl methanesulfonate (EMS) was
used as a positive control substance without metabolic
activation and cyclophosphamide (CPA) with metabolic
activation. Cells were trypsinized and counted, and the
relative cell count (RCC) was calculated. The cells were
centrifuged at ~1000 rpm for 5 min and resuspended in
5 mL of 75 mM KCl solution. After 10 min at room
temperature, 5 mL of fixative (methanol:glacial acetic
acid = 3:1 v/v) was added to the cell suspension, and
the suspension was refrigerated for ~20 min. The fixa-
tive was changed twice by centrifugation at ~1500 rpm
for 5 min. Two slides were prepared from each fixed-
cell suspension. The slides were air-dried, stained with
3% Giemsa solution, washed in tap water and distilled
water, dried, and mounted in DPX (Fluka) for chromo-
some aberration scoring. Chromosome aberrations
were identified morphologically according to the princi-
ples described in the ‘Atlas of chromosome aberration
by chemicals’ (JEMS-MMS, 1988). Cells with more than
four of the same type of aberration were scored as mul-
tiple aberrations. Any metaphase with one or more
aberrations, regardless of the type, was classified as an
aberration metaphase. Slides were scanned systemically,
and each set of metaphases was examined at 1000×
magnification. Structural chromosome aberrations were
evaluated in 100 well-spread metaphases, each contain-
ing 23–27 chromosomes. The microscopic stage coor-
dinates and each type and number of aberration were
recorded for each aberrant metaphase. The results are
expressed as the number of findings per 100 meta-
phases. Regardless of the presence of aberrations, an
additional 100 metaphases were examined to determine
the frequency of diploidy (DP), polyploidy (PP, > 37
chromosomes), and endoreduplication (ER).
In vivo MN test
MN tests using mice was conducted as described pre-
viously [10]. Specific pathogen-free male CrljOri:CD1
(ICR) mice weighing 27.2–30.0 g were obtained from
Orient Bio Co., Ltd. (Seongnam, Korea) at 6 weeks of
age. The preliminary study showed that oral adminis-
tration of ORSE at a dose of 2000 mg/kg did not in-
duce any toxic effect (data not shown). The highest
dose was determined based on the dose range-finding
study, and 2000 mg/kg, which was the limit dose for
treatment up to 14 days according to the OECD
guidelines, was selected as the maximum dose. Mice
were used in experiments after 1 week of quarantine
and acclimatization. Two slides of the cell suspension
from each animal were made. Small round or oval
bodies, measuring about 1/5 to 1/20 the diameter of a
polychromatic erythrocyte (PCE), were counted as
micronuclei. The same observer scored a total of 2000
PCEs per animal to determine the frequency of micro-
nucleated polychromatic erythrocytes (MNPCEs). The
ratio of PCEs to normochromatic erythrocytes (NCE)
[PCE/(PCE + NCE) ratio] was calculated by counting
500 cells. The mortality and external appearance of
animals were checked and recorded once a day during
the study period, and these observations were made
three times after the final administration on the final
dosing day. Body weight was measured on the days of
reception, grouping, dosing, and autopsy. This study
was approved by the Korea Institute of Toxicology
(Daejeon, Republic of Korea), and was conducted
according to the guidelines of the Institutional Animal
Care and Use Committee in the Korea Institute of
Toxicology, which is accredited by AAALAC Inter-
national (1998) under the GLP Regulations for Non-
clinical Laboratory Studies.
Statistical analyses
The statistical analyses used for the study were selected
based on the methods used in published reports [13]
using SAS software (version 9.1.3, SAS Institute Inc.,
Cary, NC, USA). Each metaphase was classified as a nor-
mal metaphase or aberrant metaphase with one or more
aberrations, and the frequency of aberrant metaphase
was analyzed statistically. The numerical aberrations
were classified into DP, PP, and ER, and the frequencies of
PP + ER were analyzed. The χ2 test and Fisher’s exact test
were performed to compare the vehicle control and
ORSE-treated groups [14]. Fisher’s exact test was used to
Lee et al. BMC Complementary and Alternative Medicine  (2015) 15:273 Page 3 of 8
compare the vehicle and positive control groups. Differ-
ences were regarded as significant at P < 0.05The in vivo
MN results were evaluated as described previously [10]
using the method of Lovell et al. [15] with minor modifi-
cation. Data with heterogeneous variances were analyzed
using Kruskal–Wallis analysis of variance followed by
multiple comparisons using Dunnett’s test [16] The sig-
nificance was accepted when all of the PCE/(PCE +
NCE) ratios were > 0.1. The result was judged as positive
when there was a significant and dose-related increase
or a reproducible increase in the frequency of MNPCEs
or aberrant metaphases at one or more dose levels.
Differences were regarded as significant at P < 0.05.
Results
HPLC analysis of ORSE
Using established conditions, three components were
eluted within 35 min in a sample analysis using mobile
phases consisting of solvent A (water) and solvent B
(acetonitrile). A typical HPLC chromatogram for ORSE
is shown in Fig. 1. The retention times of the two com-
ponents were 11.60 min (coumarin) and 14.88 min (cin-
namaldehyde). The regression equations for coumarin
and cinnamaldehyde were y = 42536.98x – 4343.49 and
y = 107074.20x – 46100.12. The correlation coefficients
(r2) of the calibration curves for the two constituents
were 1.0000 and 0.9999. These results showed that the
calibration curves showed good linearity. The contents
of two components identified in ORSE were 0.37 mg/g
and 0.05 mg/g (Table 2).
Bacterial reverse mutation assay (Ames test)
No positive mutagenic response was observed in any of
the S. typhimurium or E. coli strains tested compared
with concurrent vehicle control groups regardless of the
presence (Fig. 2a) or absence (Fig. 2b) of the S9 mix up
to 5000 μg/plate.
Chromosome aberration tests
According to our preliminary study (data not shown),
ORSE neither inhibited cell growth nor killed Chinese
hamster lung (CHL) cells. We examined the concentra-
tion range of 1250, 2500, and 5000 μg/mL, which was
most compatible with a good cell-proliferating ability
and which produced a sufficient number of metaphases
for the confirmatory assay. Therefore, we used 5000 μg/
mL as the highest exposure level and serial dilutions for
further dose–response tests.
There were no statistically significant increase in the
number of metaphase cells with structural aberrations at
Fig. 1 HPLC chromatograms of (a) the reference standard mixture and (b) ORSE: 230 nm (I), 254 nm (II), and 280 nm
Table 2 Contents of two components in the ORSE by HPLC
(n = 3)
Compound Mean (mg/g) SD RSD (%) Source
Coumarin 0.37 0.01 1.80 Cinnamomi Cortex
Cinnamaldehyde 0.05 0.00 0.06 Cinnamomi Cortex
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Fig. 2 Effect of ORSE in the bacterial reverse mutation assay (Ames test) (a) with (+S9 mix) and (b) without (−S9 mix) metabolic activation
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6 h or 22 h with or without the S9 mix in the ORSE-
treated group up 5000 μg/mL (Table 3) compared with
the vehicle control group (P < 0.01). In each positive
control group, the number of metaphases with structural
aberrations in the vehicle and positive control groups
was within the range established in historical data of the
Korea Institute of Toxicology (KIT, 2009). These find-
ings confirm that the methodologies used in this study
were valid. Therefore, under the conditions of this test,
ORSE showed a positive response in the chromosomal
aberration test.
MN test
As shown Table 4, there was no significant change in
body weight compared with the vehicle control group
between the first and final administration of ORSE at
500, 1000, or 2000 mg/kg. The number of MNPCEs/
2000 PCEs and PCE/(PCE +NCE) did not increase sig-
nificantly in the groups treated with SCRT at 500, 1000,
or 2000 mg/kg (Table 5). There was a significant in-
crease in the number of MNPCEs/2000 PCEs (50.00)
and a significant decrease in the number of PCE/(PCE +
NCE) in the positive control group (cyclophosphamide
monohydrate), indicating that the present study was per-
formed under good laboratory conditions.
Discussion
The present study demonstrated that ORSE, a traditional
herbal medicine for the treatment of various renal dis-
eases, was not genotoxic using an in vitro chromosomal
abbreviation test, an in vitro bacterial reverse mutation
assay, or an in vivo MN test. ORSE did not exhibit any
genotoxic potential in any of the test systems employed.
An in vitro chromosome aberration test using CHL
cells was performed to determine whether ORSE affects
the genotoxicity. The in vitro chromosome aberration
test is used to identify agents that induce structural
Table 3 Chromosomal aberration assay and relative cell counts of ORSE














6 h treatment (+S9)
0 + 6–18 2.0/1.0 2.0/1.0 1.0 + 0.0 100
1250 + 6–18 0.0/0.0 0.0/0.0 1.0 + 0.5 108
2500 + 6–18 0.5/0.5 0.5/0.5 0.0 + 0.0 107
5000 + 6–18 1.5/1.5 1.5/1.5 0.0+ 0.0 103
CPA 6 + 6–18 25.5/25.5** 36.0/36.0 0.5 + 0.0 78
6 h treatment (-S9)
0 - 6–18 0.0/0.0 0.0/0.0 0.5 + 0.0 100
1250 - 6–18 0.0/0.0 0.0/0.0 0.0 + 0.0 103
2500 - 6–18 1.0/1.0 1.0/1.0 0.0 + 0.0 103
5000 - 6–18 0.5/0.5 0.5/0.5 1.5 + 0.0 93
EMS 800 - 6–18 28.5/28.5** 36.0/36.0 0.0 + 0.0 64
22 h treatment (-S9)
0 - 22-2 0.0/0.0 0.0/0.0 1.0 + 0.0 100
1250 - 22-2 0.5/0.5 1.0/1.0 0.0 + 0.0 103
2500 - 22-2 0.0/0.0 0.0/0.0 0.0 + 0.0 102
5000 - 22-2 0.0/0.0 0.0/0.0 0.0 + 0.0 70
EMS 600 - 22-2 33.0/33.0** 46.5/46.5 0.5 + 0.0 58
**Significantly different from the control at P<0.01
a) Treatment time-recovery time
Table 4 Body weight changes of Micronucleus test in mice following administration of ORSE
Group Vehicle control ORSE ORSE ORSE Positive control (cyclophosphamide monohydrate)
Dose (mg/kg) 0 500 1000 2000 70
Day 1 (Mean ± S.D) 35.9 ± 1.31 37.3 ± 2.34 36.9 ± 1.31 37.2 ± 2.41 37.0 ± 1.93a)
Day 2 (Mean ± S.D) 36.0 ± 1.91 37.3 ± 2.23 36.9 ± 1.48 37.1 ± 2.44 37.7 ± 2.26
Day 3 (Mean ± S.D) 35.5 ± 1.80 37.3 ± 2.46 37.3 ± 1.51 37.4 ± 2.52 37.4 ± 2.64
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chromosomal aberrations in cultured mammalian cells
[17]. In the present in vitro chromosome aberration
test, with 6 h or 22 h treatments regardless of presence
or absence of the S9 mix, ORSE did not increase the
number of aberrant cells observed. However, to confirm
these results, more reliable tests are needed.
S. typhimurium strains TA100, TA1535, TA98, and
TA1537 and the tryptophan auxotroph strain E. coli
WP2 uvrA were used in the bacterial reverse mutation
test [18, 19]. These strains have been shown to be sensi-
tive to the mutagenic activity of a wide range of chem-
ical classes [20].
In the bacterial reverse mutation test (Ames test), we
used the histidine auxotroph S. typhimurium strains
TA100, TA1535, TA98, and TA1537 and the tryptophan
auxotroph strain E. coli WP2 uvrA [18, 19]. In the
present study, no mutagenic effects of ORSE in S.
typhimurium strains TA100, TA1535, TA98, or TA1537,
or the E. coli WP2 uvrA was observed at 555.6, 1666.7,
and 5000 μg/plate. The present tested strains have been
shown to be sensitive to the mutagenic activity of a
wide range of chemical classes. Mutation of genes
results in a deficient DNA repair system and greatly
enhances the sensitivity of these strains to certain mu-
tagens [21]. Therefore, ORSE did not appear to mutate
any genes in vitro.
MN tests have been employed for genotoxicity and
mutagenicity detection of materials that induce the for-
mation of DNA fragments [22–24]. The increased MN
frequency is related to cancer, because MN can be a
target of carcinogenesis [25, 26]. In the present study,
there was no significant or dose-related increase in the
number of MNPCEs per 2000 PCEs at any ORSE-
treatment dose level. An elevated frequency of micro-
nucleated PCEs(MNPCEs) indicates chromosomal dam-
age (Fench, Krishna). Also, no abnormal signs and body
weights were observed in any of the gropus. Therefore,
ORSE is associated with a low risk for carcinogenesis.
Conclusion
On the basis of our results, the ORSE did not exert any
genotoxicity in the battery of three assessments, in vitro
bacterial reverse mutation assay, or an in vivo MN test.
To our knowledge, this is the first published study to
demonstrated traditional herbal medicine genotoxicity
of the ORSE.
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